article · Human Vaccines & Immunotherapeutics
Some immune checkpoint inhibitors (ICI) has been used for men with specific metastatic castration-resistant prostate cancer (mCRPC). However, inconsistent results of ICI for unselected mCRPC population raise concerns. The primary outcomes were overall survival (OS) and radiographic progression-free survival (PFS), and the secondary outcomes included objective response rate (ORR). Individual patient data (IPD) were reconstructed from reported survival curve, and Kaplan-Meier method was used to evaluate the efficacy. Data of 1580 patients from 21 clinical trials were analyzed without biomarker-selected indications. The pooled 1-y and 2-y OS were 63% and 39%, while pooled 6-month and 12-month PFS were 41% and 17%. ICI plus other agent showed more OS and PFS benefits comparing with mono or dual ICI therapy (All P < .05). Combination therapy with ICI showed encouraging but preliminary signs in mCRPC. Future large trials focusing on combination regimens of ICI are needed.<b>Registration:</b> PROSPERO (CRD420251087847).
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/21645515.2026.2626084
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
